The first glucagon/GLP-1 receptor co-agonist was discovered and validated in preclinical models in 2009
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
The researchers suggested the benefits of GLP-1s before pregnancy could be negated or attenuated by the adverse effects of GLP-1 discontinuation. They added the higher risk for gestational weight gain may contribute to the increased risk for hypertensive disorders of pregnancy and gestational diabetes given the established relationship between gestational weight gain and adverse pregnancy outcomes. Maya told Healio that many individuals are on GLP-1s before pregnancy and are benefiting tremendously. Clinicians following these patients need to know that when their patients stop these medications for pregnancy, they are at risk for greater gestational weight gain and greater risk for gestational diabetes, hypertensive disorders of pregnancy and preterm delivery, she said
Understanding Your Denial Review the denial letter carefully
Most users will see noticeable improvements within 2-6 months of regular oral supplementation
Direct delivery into circulation allows the peptide to reach target tissues without the absorption loss associated with oral forms
